



New Grounds Biotech EIS Fund I
A gateway to UK Biotechnology

The Opportunity: The case for biotechnology

Why biotechnology?

A sustainable future



Earlier identification of disease risk and diagnosis, through genetic screening



New treatments for previously untreatable conditions, e.g. engineered tissue, stem cell therapies



Reduced reliance on fossil fuels through biologically-produced chemicals and fuels

Why the UK?

Backed by great science



4 of the world's top 10 universities are in the UK



The UK government has committed to life sciences as a key sector for post-covid recovery



UK is number one cluster in Europe and is third globally ***

Why New Grounds?

A new perspective



We are building a portfolio-first venture capital fund



On average, first time funds outperform mature funds**



We do not think outside of the box, we remove it

Why invest?

Financial Returns



Biotech and Healthcare produced 491% return from 2010 to 2019



US VC: Biotech outperformed the market by 8% across 2000-2018, with average IRR 27.4%**



Investment in private UK biotech companies has increased by over 400% since 2012

As an industry outsider, we bring a new perspective to biotechnology

*Association of Investment Companies (AIC) (January 2020), Top performing investment company sectors over the last decade

**<https://www.cambridgeassociates.com/wp-content/uploads/2020/02/WEB-2019-Q3-USVC-Benchmark-Book.pdf>


***<https://docs.preqin.com/press/First-Time-VC-Nov-17.pdf>

***<https://www.bioindustry.org/uploads/assets/2552f01e-5b03-47ca-9794ba0d428a6cf5/Opportunity-on-your-doorstep-A-guide-to-investing-in-the-UK-biotech-sector.pdf>



An introduction to New Grounds


New Grounds Diamond



The NG Diamond consists of three building blocks; the NG Enablers, the NG Portfolio, and the NG Community.

Interactions between these building blocks will create a unique relationship, and from this, something bigger will emerge, NG Ecosystem.

Investment Thesis



Evaluation Framework

Seven proprietary frameworks are vital to our evaluation process. Each framework has been created to reveal what is under the surface of a start-up.

These frameworks cover everything from the size of the problem being addressed to the financial risks associated with scaling.



Portfolio



Large-scale manufacturer of advanced cell culture systems it manufactures patient derived organoids (PDOs) at industry scale, beyond the capacity of competitors, using its novel and patented bioprocessor technology.



Novel graphene-based biosensor. they have developed a low-cost biosensor for use in analysing compound concentrations during drug development and production.



Led by Professor Helen McCarthy of Queen's University Belfast, pHion has developed the peptide based RALA platform for precision delivery of therapeutic vaccines.

"Identify the need. Incubate the solution. Break New Grounds."



Our Team



Mohammad Khobreh, Co-founder
Serial Entrepreneur and Investor

Mohammad is an experienced life science investor, and has both held director and advisor roles in biotech scale-ups. He experience ranges from contract drug manufacturing to establishing a biofuel refinery. He is also an Investment Committee member for a fund focused on pharmaceuticals, food and energy.



Jason Goldstein, Co-founder
Business and Life Science Advisor

Experienced business advisor having worked at EY in Tokyo, London and Leeds. During his time at EY he advised life science businesses on efficient operating models, joint ventures and more. He has worked with life science start-ups, from mental health to HR SaaS and currently leads commercialisation for a Medtech start-up, NeuroVirt.




Richard Kaschula, Scientist

Over 10 years experience in academic research, including 6 years as a post-doctoral fellow at the Francis Crick Institute. Most recently he was part of the LifeArc Fellowship, bringing experience in IP protection, academic spin-outs and licensing.



Parise Lockwood, Scientist

Currently completing her bachelor's degree at Imperial College London, Parise is passionate about microbiology and bioinformatics with a keen interest in Alzheimer's Disease.



Josh Bond, Scientist

With a master's in Biotechnology, Bioprocessing and Business Management Josh brings both knowledge and hands on experience from his time as research assistant at Trinity College Dublin.



Key Terms

Fund	New Grounds Biotech EIS Fund I
Structure	An unapproved transparent fund comprising a collective portfolio capable of attracting EIS tax reliefs
Investment Manager	The Fund Incubator
Investment Advisor	New Grounds Venture Capital Limited
Custodian and Administrator	Mainspring Nominees Limited
Minimum 1st Close	£3,000,000*
Minimum Investment	£50,000* per investment
Maximum Investment	£1,000,000* per company
Investment Focus	Early-stage biotech companies, targeting seed and series A
Minimum Portfolio	5 companies per investor
Target Portfolio	6* companies per investor
Investment Period	Investor capital deployed within 18 months from close*. Investment term to be targeted between 3-7 years in order to benefit from tax reliefs.

*At the discretion of the Investment Manager and Investment Advisor
 ** Note there is no guarantee targets can or will be reached

Target Return	The targeted return before EIS tax relief and management fees is 3x Return on Investment (RoI). Performance, however, and development of early-stage companies is unpredictable.**
1st Close	31 July 2021
Annual Fund	The Fund is the first of a series of funds raised annually
Set Up Fee	The Set Up Fee will be 2% of Subscriptions aggregate in advance covering all set-up costs.
Management Fee	The Management Fee will be 2% of your Subscriptions per annum for 5 years, payable from Subscriptions. After the initial 5 year period, then for each year you continue to have investments in the Fund, the annual Management Fee will be 1% of the gross value of all of your Investments, payable from returns. This fee includes all day-to-day custodian charges (annual administrative and dealing) charges.
Performance Fee	The Fund charges a performance fee of 20%. Such fee is payable once the Investor has received an amount equal to their Subscriptions.
Costs & Expenses	The Investment Advisor will carry the entire running costs of the Fund. Any ad-hoc requests over and above the running of the fund may still be payable and are set out in clause 10 of the Investment Management Agreement.





Contact us for more information
info@ngvc.co.uk